ArticleVirology journal2025
Isolation and characterization of phages ΦZC2 and ΦZC3 against carbapenem-resistant Acinetobacter baumannii, and efficacy of ΦZC3 on A549 cells.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A novel Acinetobacter phage reveals altered virulence traits in phage-resistant strains.Virulence · 2026Article
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Efficacy of phage vB_EcoP_ZCEC16 in controlling Escherichia coli contamination in fresh poultry meat.BMC microbiology · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metagenome-based insights into bacteriophage diversity of an urban river ecosystem.Molecular biology reports · 2026Article
- Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Large-genome phage vB_Eco_ZCEC15 targets gastrointestinal MDR E. coli: evidence from in vitro and Caco-2 cell models.BMC microbiology · 2026Article
- Prophylactic and therapeutic efficacy of Acinetobacter phage RM_A1 against carbapenem-resistant Acinetobacter baumannii with no cytotoxicity to human skin cells.BMC microbiology · 2026Article
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- Phage therapy for multidrug-resistant pulmonary infections: bridging precision matching, lung delivery, host immunity, and clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Genomic and functional characterization ofFrontiers in microbiology · 2026Article
- Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcinetobacter baumannii is an opportunistic pathogen and a major causative agent of hospital-acquired infections. This pathogen can acquire various antibiotic resistance genes, including those conferring resistance to last-resort antibiotics such as carbapenems. MDR A. baumannii is known to cause several infections, including pneumonia and urinary tract infections. Consequently, there is an urgent need to explore alternative therapies, and bacteriophage (phage) has emerged as a promising therapeutic approach for combating multidrug-resistant (MDR) infections. MATERIALS AND
methodsThis study investigates the therapeutic potential of specific bacteriophages against MDR, particularly carbapenem-resistant A. baumannii, and evaluates lytic activity against 41 clinical isolates of MDR A. baumannii. The phages morphotypes were identified by transmission electron microscope. The stability of these phages was assessed under different conditions, including pH (2, 3, 4, 7, and 10-12), temperature (-80, -20, 4, 37, 50, 60, 70, and 80
resultsTwo phages, vB_AbaP_ZC2 (ΦZC2) and vB_AbaM_ZC3 (ΦZC3), were isolated from hospital wastewater in Egypt. The phages demonstrated lytic activity against 24.3% (n = 10) and 31.7% (n = 13) of the isolates, respectively. Phage ΦZC2 demonstrated high EOP values (0.75-1) against AB23 and AB26, moderate activity on AB34 and AB35 (EOP = 0.19), and low or no activity on AB10, AB24, and AB31. Similarly, phage ΦZC3 exhibited high EOP on AB24 (EOP = 1), moderate levels on AB12, AB29, and AB38, while showing low or no efficacy against the remaining tested isolates. The morphotypes of ΦZC2 and ΦZC3 are podovirus and myovirus, respectively. The two phages were amplified using a bioreactor and reached titers of approximately 10¹⁰ PFU/ml in 2 L.ΦZC2 was stable at a pH range from 3 to 12 approximately 10
conclusionIn this study, the two lytic phages have antibacterial activity against MDR A. baumannii. particularly, ΦZC3 can be a potential therapy for pulmonary infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.